We evaluated the ability of a short course of treatment with the ribonucleotide reductase (RR) inhibitor hydroxyurea (HU) and two novel RR inhibitors Trimidox (TX) and Didox (DX) to influence late-stage murine retrovirus-induced lymphoproliferative disease. LPBM5 murine leukaemia virus retrovirus-infected mice were treated daily with HU, TX or DX for 4 weeks, beginning 9 weeks post-infection, after development of immunodeficiency and lymphoproliferative disease. Drug effects on disease progression were determined by evaluating spleen weight and histology. Effects on haematopoiesis were determined by measuring peripheral blood indices (white blood cells and haematocrit) and assay of femur cellularity and femoral and splenic content of colony-forming units granulocytemacrophage (CFU-GM) and burst-forming unitserythroid (BFU-E). HU, TX and DX partially reversed late-stage retrovirus-induced disease, resulting in spleen weights significantly below pre-treatment values. Spleen histology was also improved by RR inhibitor treatment (DX>TX>HU). However, as expected, HU was significantly myelosuppressive, inducing a reduction in peripheral indices associated with depletion of femoral CFU-GM and BFU-E. In contrast, although TX and DX were moderately myelosuppressive, both drugs were significantly better tolerated than HU. In summary, short-term treatment in late-stage murine retroviral disease with HU, TX or DX induced dramatic reversal of disease pathophysiology. However, the novel RR inhibitors TX and DX had more effective activity and significantly less bone marrow toxicity than HU.
The ribonucleotide reductase (RR) inhibitor hydroxyurea (HU) has been used successfully as a component of highly active antiretroviral therapy for some HIV-1-infected individuals (Biron et al., 2000; Rutschmann et al., 2000) . Increasingly, HU is being included in multidrug regimens only in patients who have failed to respond to protease inhibitor-containing regimens (Grunke et al., 1999; Youle et al., 2002) . However, general appeal for the use of this compound has been limited due to its propensity to induce bone marrow toxicity. In patients with advanced HIV disease, in those receiving other drugs that suppress haematopoiesis (for example, zidovudine) or in heavily pretreated patients, the bone marrow suppression associated with HU may be exacerbated (Maserati, 1999) .
We have been evaluating two novel RR inhibitors, Trimidox (TX; 3,4,5-trihydroxybenzamidoxime) and
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Didox, (DX; 3,4-dihydroxbenzohydroxamic acid) as potential anti-HIV compounds (Mayhew et al., 1997; 2002; Ussery et al., 1999) . TX and DX have been shown to inhibit disease progression in the murine AIDS model of retrovirus infection (Mayhew et al., 1997; 2002) and to reduce HIV-1 RNA titres in HIV-infected HuPBMC SCID mice (Broud et al., 1998; Ussery et al., 1999) . Although both TX and DX are more potent in vitro inhibitors of RR activity than HU (Elford & van't Riet 1985; Szekeres et al., 1994) , they have less in vivo bone marrow toxicity than HU when administered to normal mice (Mayhew et al., 1999) . Additionally, equimolar concentrations of TX and DX are less inhibitory to the in vitro growth of murine and human CFU-GM and BFU-E than HU (Mayhew et al., 1999) . The purpose of present study was to expand on these observations by investigating the haematopoietic toxicity of TX, DX and HU when administered to immunodeficient mice in late-stage disease.
Murine AIDS is induced by infection of susceptible mice with the LPBM5 murine leukaemia virus (MuLV) complex of retroviruses ( Jolicoeur, 1991; Morse, et al., 1992) . Many features of early-stage LPBM5 MuLVinduced disease in murine AIDS are similar to those in human AIDS, including development of profound immunodeficiency, suppression of haematopoiesis, abnormal Tand B-lymphocyte function, polyclonal B-cell activation and proliferation associated with progressive lymphadenopathy, splenomegaly and hypergammaglobulinaemia. Also in common with human AIDS, advanced disease is associated with enhanced susceptibility to opportunistic infections and development of secondary neoplasms ( Jolicoeur, 1991; Morse et al., 1992; Mosier, 1996) . LPBM5 MuLV infected mice usually die between 8 and 16 weeks post-infection (Hartley et al., 1989) , with the cause of death thought to be due to severe pulmonary compromise secondary to lymphoid cell infiltration and enlarged thoracic lymph nodes (Morse et al., 1992) . As infected Blymphocyte activation and proliferation are a major component of LPBM5 MuLV-induced disease (Klinman & Morse, 1989) , murine AIDS provides a good model for pre-clinical evaluation of compounds like HU that have been proposed to be beneficial in HIV-1 infection due in part to their cytostatic properties Lori & Lisziewicz, 2000) .
The experiments reported in this paper demonstrate that the RR inhibitors HU, TX and DX reverse retrovirusinduced splenomegaly and normalize the histological appearance of spleens to pre-treatment levels when administered to retrovirus-infected animals in late-stage disease. Importantly, the therapeutic benefit of TX and DX was achieved with significantly less bone marrow toxicity than with HU.
Materials and methods

Mice
Female C57BL/6 mice aged 8-10 weeks were purchased from Charles River/NCI (Bethesda, Md., USA), and were housed in micro-isolator cages in a temperature-and humidity-controlled environment. Mice were fed Purina Lab Chow and water ad libitum. The experimental animal protocol used in these studies was approved by the University of Kentucky IACUC committee.
Infection of mice with LPBM5 MuLV
The G6 subclone of chronically LPBM5 MuLV infected SC-1 cells was kindly provided by Dr Donald Cohen, Department of Microbiology and Immunology, University of Kentucky. G6 cells were grown in DMEM supplemented with 10% fetal bovine serum (Sigma Chemical Co., St Louis, Mich., USA) and 1% penicillin-streptomycin (Gibco, Grand Island, NY, USA). Virus was prepared for inoculation from sub-confluent G6 cells by removal of the cell supernatant. The cell monolayer was subsequently lysed (by repeated freeze-thaw cycles) to yield intracellular virus. This was then combined with the cell supernatant, centrifuged at 300×g for 10 min and 0.45-µm filtered. Inoculation was performed with freshly prepared virus stock by two separate 0.5 ml intraperitoneal (i.p.) injections per mouse, 3 days apart. Drug treatment of retrovirusinfected animals was started at 9 weeks post-infection, once peripheral lymphadenopathy and splenomegaly, characteristic signs of disease progression (Morse et al., 1992) , had appeared.
Drug treatment
After 9 weeks of virus incubation, several infected mice were sacrificed to establish the extent of disease progression as a pre-treatment baseline. Mice were then randomly assigned to receive TX (175 mg/kg/day), DX (350 mg/kg/day) or HU (200 mg/kg/day) monotherapy. Drug doses were the same as those previously shown to have optimal activity when administered to LPBM5 MuLVinfected mice in early-stage infection . Uninfected and infected mice receiving no drug treatment served as normal and infected controls, respectively. Drugs were administered by daily intraperitoneal injection (7 days per week) for a period of 4 weeks. At the conclusion of treatment (that is, week 13), mice in each experimental group were sacrificed to evaluate the effects of drug treatment on retroviral-induced disease progression (that is, gross morphology, splenomegaly and histological examination) and on haematopoiesis (that is, peripheral blood indices, femur cellularity and numbers of CFU-GM and BFU-E per femur and spleen).
Reversal of late-stage murine AIDS by RR inhibitors
Spleen histopathology
At weeks 9 and 13, spleens from control and drug treated animals were evaluated for drug effects on retroviralinduced lymphoproliferative disease. Spleens were fixed in 10% neutral buffered formalin, embedded in paraffin and sectioned at 6-8 mm. Sections were processed through graded alcohols to xylene and stained with haematoxylin and eosin. The stained sections were then examined by routine light microscopy.
Haematopoeitic progenitor cell assay
The mean content of committed haematopoietic progenitors (CFU-GM and BFU-E) per femur and spleen of normal and infected controls and infected mice treated with RR inhibitors was determined as follows. At each time point, one femur from each animal was rapidly removed and immediately placed on ice. The contents of each femur were flushed in ice-cold PBS using a 22-gauge needle. A single cell suspension was then obtained by repeated gentle flushing through a 19-gauge needle and nucleated cells counted using a Coulter Counter (model ZM, Coulter Electronics, Hileah, Fla., USA). Individual animal femoral cellularity was then calculated and bone marrow cells were pooled for evaluation of the femoral content of haematopoietic progenitor cells in a colonyforming assay. Splenocytes were obtained by disruption of spleens in 5 ml ice-cold PBS followed by passage through a sterile nylon screen. Then 5×10 4 /ml bone marrow cells or 2.5×10 5 /ml splenocytes were added to methylcellulose media optimized to promote the growth of murine CFU-GM and BFU-E (Stem Cell Technologies; Vancouver, BC, Canada; Cat # M3430). Growth media contained 1% methylcellulose in Iscove's minimal Dulbecco's media, 15% FBS, 1% bovine serum albumin, 10 mg/ml bovine pancreatic insulin, 200 mg/ml human transferrin (iron saturated), 10 -4 M 2-mercaptoethanol, 2 mM L-glutamine, 50 ng/ml recombinant murine (rm) stem cell factor, 10 ng/ml rm-interleukin-3, 10 ng/ml recombinant human (rh) interleukin-6 and 3 units/ml rh-erythropoietin. After vortexing, 1 ml of media was plated in duplicate in a sixwell tissue culture plate and incubated at 37°C in air containing 5% CO 2 for 10 days. Using an inverted microscope, CFU-GM and BFU-E were identified on the basis of their morphology and colonies containing greater than 50 cells were scored. The numbers of CFU-GM and BFU-E per femur was determined using the following calculation: mean number of haematopoietic colonies scored multiplied by the mean number of cells per femur, divided by 50000. Numbers of CFU-GM and BFU-E per spleen were determined relative to normal controls at weeks 9 and 13 by dividing the mean number of colonies scored by the mean spleen weight of each experimental group.
Statistical analysis
To determine whether differences between experimental groups were statistically significant, a two-tailed t-test was performed. A P value of less than 0.05 was considered statistically significant. P values are indicated in the text where appropriate.
Results
RR inhibitors reverse peripheral lymphadenopathy and splenomegaly in late-stage infection
At 9 weeks post-infection all infected animals showed characteristic signs of LPBM5 MuLV disease (peripheral lymphadenopathy and splenomegaly). At week 13, infected mice treated with RR inhibitors exhibited fewer signs of peripheral lymphoproliferative disease than infected controls. Lymphadenopathy (clearly visible in infected controls, particularly in the thoracic region) was absent from drug treated mice. Additionally, spleens were palpable in infected controls, but not palpable in drug treated animals. Upon autopsy, gross morphological analysis revealed massively enlarged peripheral lymph nodes in infected controls (data not shown). In contrast, peripheral lymphadenopathy was absent and spleen weights were greatly reduced in all drug-treated animals compared with infected controls (DX>TX>HU; Figure 1a ,b). Spleen weights of drug-treated animals were not only significantly lower than infected controls at week 13, but significantly lower than baseline infected controls (week 9; P<0.01).
RR inhibitors improve splenic histology
Histological examination revealed that, at week 13, spleens from normal controls consisted of approximately 40% white pulp (lymphoid cells) with normal red and white pulp architecture (Figure 1c, top left) . In contrast, all infected control animals showed a diffuse proliferation of intermediate-to-large size lymphoid cells involving the splenic white pulp. White pulp expansion was largely confluent (approximately 85% of total spleen mass at baseline and week 13) and was associated with almost complete obliteration of splenic red pulp (Figure 1c , top middle and right). In contrast, RR inhibitor treated animals showed evidence of reduced splenic lymphoproliferation. The extent of disease was dramatically reversed in TX and DX treated animals compared with infected controls, with partial restoration of white and red pulp splenic architecture (Figure 1c , bottom left and middle). DX was associated with the most effective reversal of disease, with approximately 60% of total spleen mass consisting of white pulp after 4 weeks of treatment. The spleens of TX treated animals contained approximately 80% white pulp. However, these areas were less widespread than infected controls without loss of normal architecture or obliteration of the 
Effect of RR inhibitor treatment on body weights
Although several untreated mice were moribund, all LPBM5 MuLV-infected control mice survived to week 13. The pre-treatment body weight of infected controls (week 9) was approximately 24.9 g and by week 13, infected control body weight had increased slightly to 26.8 g (Table 1) . Conversely, TX, DX and HU treatment was associated with a reduction in body weight. DX and HU treated animals weighed slightly but significantly lower than normal and infected controls at week 13 (Table 1 ; P<0.05). TX treated animals weighed slightly but not significantly lower than controls. No animal receiving drug treatment was moribund at the conclusion of treatment, indicating that these treatments were well tolerated.
HU reduces peripheral blood indices more than TX or DX
Retrovirus infection by itself resulted in decreased white blood cell counts compared with normal controls (Figure  2a) , and RR inhibitor treatment further reduced the white blood cell count (HU>TX>DX). At week 13, TX and DX had induced a significant reduction in white blood cell count (approximately 55%) compared with normal controls (P<10 -5 ). Animals treated with HU had even lower numbers of white blood cells, which were reduced by 65% compared with normal at week 13 (P<10 -5 ). Retrovirus infection also suppressed red blood cell production, resulting in a haematocrit 10% lower than normal at week 13 (Figure 2b ). Treatment with TX or DX had little additional effect on this parameter. Both drugs induced a slight decrease, and although this resulted in significantly lower haematocrit levels than normal animals (P<0.01), this decrease was not significantly different from infected controls. In contrast, at week 13, HU had reduced the haematocrit by 45%, a highly significant decrease compared with infected controls (P<10 -5 ).
HU depletes femoral CFU-GM and BFU-E more than TX or DX
Retrovirus infection did not significantly alter the numbers of nucleated cells per femur. However, drug treatment of infected animals was associated with significant declines in femur cellularity (Figure 3a) . At week 13, TX and DX had reduced the femur cellularity by approximately 35% and 45%, respectively, compared with controls (P<0.001).
However, the most dramatic changes were induced by HU, which resulted in 70% fewer cells per femur than controls at week 13 ( Figure 3a ; P<10 -6 ). Analysis of numbers of committed haematopoietic progenitors CFU-GM and BFU-E per femur revealed that retroviral infection induced a decrease in both CFU-GM and BFU-E by week 9, which had rebounded to levels close to normal controls at week 13 (Figure 3b ). Treatment with TX did not inhibit the increase in femoral CFU-GM; indeed at week 13 numbers of CFU-GM in TX treated mice were higher than controls. DX resulted in slightly (but not significantly) lower CFU-GM levels than infected controls at week 13. In contrast, HU treatment was associated with a large decrease in femoral content of CFU-GM (about 80%), which was significantly lower than infected controls (P<10 -4 ). Numbers of femoral BFU-E in infected controls was substantially decreased by week 9, but had rebounded to slightly above normal at week 13. Compared with CFU-GM, femoral BFU-E were more sensitive to TX and DX. Numbers of BFU-E per femur in TX and DX treated animals were increased from pre-treatment levels (week 9), but were significantly lower than controls at week 13 (approximately 60%; P<0.001). Conversely, HU treatment depleted femurs of BFU-E, which at week 13 were less than 10% of control levels (P<10 -4 ). Retroviral infection alone induced significant splenic extramedullary haematopoiesis, characterized by 10-and fourfold increases in CFU-GM and BFU-E per spleen at week 9 (Figure 3c) . However, by week 13 numbers of CFU-GM and BFU-E per spleen in infected controls had declined significantly (but were still two-to threefold greater than normal controls). RR inhibitor treatment was also associated with a dramatic decline in the numbers of CFU-GM and BFU-E per spleen between weeks 9 and 13 (60% lower than normal controls; P<0.001). Reductions in splenic haematopoiesis associated with TX and DX are likely due to an antiviral effect rather than haematopoietic toxicity because the bone marrow in these animals is adequately producing white and red blood cells (Figures 2 and  3a,b) .
Discussion
In this study we have shown that a short course of treatment with the RR inhibitors HU, TX and DX favourably affects late-stage murine retrovirus-induced lymphoproliferative disease. This is demonstrated by the ability of these compounds to reduce splenic tumour mass to below pretreatment levels and to partially normalize splenic histology (Figure 1 ). We also show that HU, an RR inhibitor in current clinical use for HIV-1 infection, was significantly more myelosuppressive than the novel RR inhibitors TX and DX, as evidenced by reductions in peripheral blood indices (Figure 2) , associated with depletion from the bone marrow of committed haematopoietic progenitor cells (Figure 3) . We have previously demonstrated that treatment of uninfected mice with TX (220 mg/kg/day) and DX (460 mg/kg/day) for 32 weeks was well tolerated, with minimal haematopoietic toxicity and no mortality (Mayhew et al., 1997) . In a further study, uninfected mice were treated with TX (220 mg/kg/day) or DX (460 mg/kg/day) for 10 weeks, and a more detailed evaluation of blood and bone marrow parameters demonstrated that both compounds induced minimal perturbations in haematopoiesis. This was in marked contrast to HU (500mg/kg/day), which was significantly myelosuppressive, inducing major changes in blood cell formation in the bone marrow associated with development of extramedullary splenic haematopoiesis (Mayhew et al., 1999) . The data reported in this paper supports our previous observations that therapeutic doses of HU are significantly more myelosuppressive than TX or DX (Mayhew et al., 1999 (Mayhew et al., , 2002 . However, it should be noted that in contrast to their effects on haematopoiesis in normal mice (Mayhew et al., 1999) , or in early-stage murine retrovirus disease , TX and DX were moderately myelosuppressive when administered to late-stage retrovirus-infected mice in this study. Importantly, this study shows that these compounds are clearly superior to HU in their ability to effectively reverse retrovirus-induced lymphoproliferation, but with significantly less bone marrow suppression.
Various antiretroviral compounds, including zidovudine (Ohnota et al., 1990; Portnoi et al., 1990) , PMPA (Suruga et al., 1998) , ribavirin (Harvie et al., 1996) and glutathione (Palamara et al., 1996) have been shown to inhibit development of LPBM5 MuLV disease. However, these treatments were typically started a short time after virus inoculation. To our knowledge, the present study is the first to demonstrate the ability of drug treatment to reverse LPBM5 MuLV retroviral disease when administered only after development of significant immunodeficiency and lymphoproliferation.
Drug monotherapy is no longer considered a viable approach for treatment of HIV infection. HU has been CN Mayhew et al. evaluated as monotherapy in HIV-infected individuals but had no effect on plasma viral RNA and induced significant bone marrow suppression (Giacca et al., 1996) . On the other hand, HU has been shown to be effective when administered to HIV patients in primary infection, in combination with inhibitors of viral reverse transcriptase and protease (Lori, 1999; Rodriguez et al., 2000) . However, in part because of fears about toxicity (Havlir et al., 2001; Zala et al., 2002) HU is currently most often used as part of a salvage regimen after failure of standard drug therapies including RT inhibitors and protease inhibitors (Grunke et al., 1999; Lafeuillade et al., 2002; Youle et al., 2002) . Unfortunately, individuals who have been heavily pretreated and/or who are in late-stage disease are most likely to exhibit the most severe HU related myelosuppression (Maserati, 1999) . Our data suggest that TX and DX may be viable alternatives to HU in both early-stage and late-stage (this study) retroviral disease.
Since HIV-1 infection is characterized by T cell activation with the most efficient virus replication only occurring in activated T cells (Stevenson et al., 1990) , the cytostatic property of HU has been proposed as the mechanism for its anti-HIV-1 action (Lori, 1999) . In support of this hypothesis are mathematical models that propose that inhibition of CD4 cell proliferation and therefore HIV-1 target cell availability, accounts for the anti-HIV-1 effect of the combination of HU and didanosine (De Boer et al., 1998) . Additionally, the numbers of activated CD8 cells increases dramatically in HIV-1 infection (Giorgi et al., 1993) , and CD8 cells have been implicated to be responsible for the immunopathology in HIV infection (Zinkernagel & Hengartner, 1994) . The inclusion of a cytostatic drug in HIV therapy that 'cools down' the immune system may therefore have beneficial effects on HIV disease progression . As RR inhibitors it is possible that TX and DX may have in common with HU the potentially beneficial effects seen on CD4 and CD8 cell activation in human AIDS (Lori, 1999) .
RR inhibitors in general may have the advantage over protease inhibitors of lower cost, lower pill burdens and less complicated administration schedules. This is a particularly important consideration for many of the nations hardest hit by the AIDS epidemic. Indeed, the use of HU in combination with didanosine has been suggested as a viable alternative to protease inhibitor containing regimens for use in Africa (Sanne et al., 2001) . Additionally, TX and DX have pharmacological properties that might make them more attractive compounds for HIV treatment than HU. For example, free radical generation has been shown to contribute to several aspects of HIV pathogenesis (reviewed in Pace & Leaf, 1995) , and both TX and DX are significantly more potent free-radical scavengers than HU (Elford et al., 1980; Rauko et al., 1997) . Also, unlike HU, TX and DX have been shown to deplete not only the purine, but also the pyrimidine deoxynucleotide triphosphate pools in various cells types (Tihan et al., 1991; Szekeres et al., 1994) . We speculate that TX and DX may therefore enhance the activity of a larger number of deoxynucleoside reverse transcriptase inhibitors than HU. Finally, TX and DX are also extremely effective iron chelators (Szekeres et al., 1995; Fritzer-Szekeres et al., 1998) . As the increasing body iron stores associated with HIV progression have been shown to indirectly enhance HIV replication and may also be associated with decreased survival (Boelaert et al., 1996; de Monye et al., 1999) , it is possible that potent iron chelators might provide significant therapeutic benefit.
In summary, we report partial reversal of late-stage retrovirus-induced lymphoproliferative disease by the RR inhibitors HU, TX and DX. Importantly, the activity of TX and DX in this model was achieved with less bone marrow toxicity than that associated with HU. Studies are ongoing in our laboratory to evaluate the comparative effects of longer-term treatment with TX, DX and HU on disease progression and long-term survival of LPBM5 MuLV retrovirus-infected mice when therapy is started in latestage disease. Because TX and DX appear to be more myelosuppressive in late-stage than in early-stage murine retrovirus disease, these compounds may have significant toxicity when administered long term to individuals in latestage HIV-1 infection. Therefore, evaluation of the bone marrow toxicity induced by these drugs during a longer course of treatment in late-stage murine AIDS will be critical. We are also endeavoring to identify the mechanism by which TX and DX, which have been well documented to inhibit RR more effectively than HU in vitro (Elford & van't Riet, 1985; Szekeres et al., 1994) , have more potent activity in vivo but with less bone marrow toxicity than HU.
